Product name: Atosiban Acetate

Molecular Formula: C₄₃H₆₇N₁₁O₁₂S₂ 

Molecular Weight: 994.2 

CAS No.: 90779-69-4

Quality standard: enterprise standard, 98% up by HPLC

Sequence: c[Mpa-D-Tyr(Et)-Ile-Thr-Asn-Cys]-Pro-Orn-Gly-NH2

Appearance: White powder 

Specific Optical Rotation (c=1,1%HAc): -45.0~-55.0° 

Water Content(Karl Fischer): ≤5.0% 

Acetate Content(by HPLC): ≤15.0% Amino Acid Composition :±10% of theoretical 

Purity(by HPLC): ≥98.0% 

Single Impurity(by HPLC): ≤1.0% 

Peptide Content(by %N): ≥80% 

Assay(By Anhydrous, Acetic Acid-free ): 95.0~105.0% 

Bacterial Endotoxins: ≤5EU/mg 

Density: 1.254 g/cm³

Bioling Point: 1469ºC at 760 mmHg

Flash Point: 842.2ºC

Refraction Optical Ratio: 1.549 

Usage: Atosiban is an oxytocin receptor blocking agent in the treatment of experimental endometriosis and was shown exhibit significant therapeutic efficiency.

Storage: Keep in a cool(2~8 °C) & dry place protected from light, keep package close when not in use.

Description:

Atosiban  is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985.[1] Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.